September 26, 2008

Sanofi Pasteur Acquires Acambis for GBP285 Million

Sanofi Pasteur has announced that Sanofi Pasteur Holding has completed the acquisition of Acambis, a manufacturer of vaccines, for GBP285 million. Pursuant to the acquisition, Acambis becomes a wholly owned subsidiary of Sanofi Pasteur Holding, the parent company of Sanofi Pasteur, the vaccines division of the Sanofi-Aventis Group.

It is reported that the integration of Acambis's activities strengthens Sanofi Pasteur's vaccine pipeline of vaccines in development to better answer global health needs. Acambis's existing manufacturing capabilities will complement and enhance those already in place within Sanofi Pasteur's global operation. The combination of both companies expertise in the production of vaccines will maximize the prospects for ongoing projects, said Sanofi Pasteur.

Sanofi Pasteur will also broaden its public health mission by honoring a 10-year contract signed by Acambis in April 2008 to produce ACAM 2000 smallpox vaccine for the US government strategic national stockpile.

Sanofi Pasteur was already developing three vaccines in partnership with Acambis - vaccines against dengue, Japanese encephalitis and West Nile virus. An efficacy study of the vaccine against dengue is set to begin by the end of 2008. The vaccine against Japanese encephalitis is in Phase III of development. First filings for registration are planned in 2009. The vaccine against West Nile virus is in Phase II of development with results of this study expected by the end of 2008.

Wayne Pisano, president and CEO of Sanofi Pasteur, said: "This acquisition is a logical and strategic step, building upon Sanofi Pasteur and Acambis's decade long partnership to develop novel vaccines. Acambis's skilled workforce of individuals who share our passion for vaccines and prevention of infectious diseases will contribute to our efforts in answering unmet medical needs of people around the world. We look forward to welcoming them into Sanofi Pasteur's organization and joining us in writing new pages of vaccine history."